Literature DB >> 20340170

Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression.

Neil M Richtand1, Yanhong Liu, Rebecca Ahlbrand, Juliana R Sullivan, Amy Hauck Newman, Robert K McNamara.   

Abstract

Dopamine D3 receptors have the highest dopamine affinity of all dopamine receptors, and may thereby regulate dopamine signaling mediated by volume transmission. Changes in D3 receptor isoform expression may alter D3 receptor function, however, little is known regarding coordination of D3 isoform expression in response to perturbations in dopaminergic stimulation. To determine the effects of dopamine receptor stimulation and blockade on D3 receptor alternative splicing, we determined D3 and D3nf isoform mRNA expression following treatment with the D3 receptor antagonist NGB 2904, and the indirect dopamine agonist amphetamine. Expression of tyrosine hydroxylase (TH) mRNA, the rate-limiting enzyme in dopamine synthesis, was also determined. The D3/D3nf mRNA expression ratio was increased in ventral striatum, prefrontal cortex, and hippocampus 6 h following D3 antagonist NGB 2904 treatment, and remained persistently elevated at 24 h in hippocampus and substantia nigra/ventral tegmentum. D3 mRNA decreased 65% and D3nf mRNA expression decreased 71% in prefrontal cortex 24 h following amphetamine treatment, however, these changes did not reach statistical significance. TH mRNA expression was unaffected by D3 antagonist NGB 2904, but was elevated by amphetamine in ventral striatum, hippocampus, and prefrontal cortex. These findings provide evidence for an adaptive response to altered D3 receptor stimulation involving changes in D3 receptor alternative splicing. Additionally, these data suggest D3 autoreceptor regulation of dopamine synthesis does not involve regulation of TH mRNA expression. Finally, the observation of regulated TH mRNA expression in dopamine terminal fields provides experimental support for the model of local control of mRNA expression in adaptation to synaptic activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20340170      PMCID: PMC2888922          DOI: 10.1002/syn.20770

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  34 in total

1.  The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes mislocalization of D3 receptors.

Authors:  K D Karpa; R Lin; N Kabbani; R Levenson
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

Review 2.  Translational control at the synapse.

Authors:  Huidong Wang; Henri Tiedge
Journal:  Neuroscientist       Date:  2004-10       Impact factor: 7.519

3.  Luteinizing hormone release from dissociated pituitary cells by dimerization of occupied LHRH receptors.

Authors:  H Gregory; C L Taylor; C R Hopkins
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

4.  Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration.

Authors:  Neil M Richtand; Jeffrey A Welge; Beth Levant; Aaron D Logue; Scott Hayes; Laurel M Pritchard; Thomas D Geracioti; Lique M Coolen; S Paul Berger
Journal:  Neuropsychopharmacology       Date:  2003-04-16       Impact factor: 7.853

5.  The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion.

Authors:  Laurel M Pritchard; Amy Hauck Newman; Robert K McNamara; Aaron D Logue; Benjamin Taylor; Jeffrey A Welge; Ming Xu; Jianhua Zhang; Neil M Richtand
Journal:  Pharmacol Biochem Behav       Date:  2007-03-06       Impact factor: 3.533

Review 6.  D3 dopamine receptor, behavioral sensitization, and psychosis.

Authors:  N M Richtand; S C Woods; S P Berger; S M Strakowski
Journal:  Neurosci Biobehav Rev       Date:  2001-07       Impact factor: 8.989

7.  N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.

Authors:  Amy Hauck Newman; Jianjing Cao; Christina J Bennett; Michael J Robarge; Rebekah A Freeman; Robert R Luedtke
Journal:  Bioorg Med Chem Lett       Date:  2003-07-07       Impact factor: 2.823

8.  Evidence for a differential medial prefrontal dopamine D1 and D2 receptor regulation of local and ventral tegmental glutamate and GABA release: a dual probe microdialysis study in the awake rat.

Authors:  M Harte; W T O'Connor
Journal:  Brain Res       Date:  2004-08-13       Impact factor: 3.252

9.  Susceptibility to amphetamine-induced place preference is predicted by locomotor response to novelty and amphetamine in the mouse.

Authors:  Cristina Orsini; Francesca Buchini; Pier Vincenzo Piazza; Stefano Puglisi-Allegra; Simona Cabib
Journal:  Psychopharmacology (Berl)       Date:  2003-11-04       Impact factor: 4.530

Review 10.  Insulin receptors, receptor antibodies, and the mechanism of insulin action.

Authors:  C R Kahn; K L Baird; J S Flier; C Grunfeld; J T Harmon; L C Harrison; F A Karlsson; M Kasuga; G L King; U C Lang; J M Podskalny; E Van Obberghen
Journal:  Recent Prog Horm Res       Date:  1981
View more
  5 in total

1.  Neurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures.

Authors:  A S Bazyan; G van Luijtelaar
Journal:  ISRN Neurol       Date:  2013-05-07

Review 2.  Immunomodulatory Effects Mediated by Dopamine.

Authors:  Rodrigo Arreola; Samantha Alvarez-Herrera; Gilberto Pérez-Sánchez; Enrique Becerril-Villanueva; Carlos Cruz-Fuentes; Enrique Octavio Flores-Gutierrez; María Eugenia Garcés-Alvarez; Dora Luz de la Cruz-Aguilera; Emilio Medina-Rivero; Gabriela Hurtado-Alvarado; Saray Quintero-Fabián; Lenin Pavón
Journal:  J Immunol Res       Date:  2016-10-04       Impact factor: 4.818

Review 3.  Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.

Authors:  Abdeslam Chagraoui; Giuseppe Di Giovanni; Philippe De Deurwaerdère
Journal:  Biomolecules       Date:  2022-02-01

Review 4.  Abnormalities of Dopamine D3 Receptor Signaling in the Diseased Brain.

Authors:  G Aleph Prieto
Journal:  J Cent Nerv Syst Dis       Date:  2017-08-16

Review 5.  Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  Biomedicines       Date:  2021-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.